Ferenci, Peter <br/><br/>
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.  [electronic resource] 

 -  Journal of viral hepatitis  06 2019 
 - 685-696 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2893 
<br/><br/><label>Standard No.: </label>10.1111/jvh.13080  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anilides--therapeutic use<br/>Antiviral Agents--therapeutic use<br/>Carbamates--therapeutic use<br/>Cyclopropanes<br/>Drug Interactions<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--drug effects<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Internationality<br/>Lactams, Macrocyclic<br/>Macrocyclic Compounds--therapeutic use<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Prospective Studies<br/>Ribavirin--therapeutic use<br/>Ritonavir--therapeutic use<br/>Sulfonamides--therapeutic use<br/>Sustained Virologic Response<br/>Uracil--analogs & derivatives<br/>Valine<br/>Young Adult